OncLive TV

Marcella Ali Kaddoura, MD, discusses challenges in integrating whole genome sequencing into routine clinical practice for myeloma.

Thierry André, MD, discusses the efficacy of nivolumab plus ipilimumab vs nivolumab monotherapy in MSI-H/dMMR mCRC.

Martin Dreyling, MD, discusses ongoing trials exploring chemotherapy-free strategies in mantle cell lymphoma using BTK inhibitors.

Toni K. Choueiri, MD, discusses the significance of targeting HIF-2α using NKT2152 in previously treated advanced clear cell renal cell carcinoma.

Aditya Shreenivas, MD, MS, discusses the association between MUC1 and Claudin 18 in GI cancers.

David Samuel Dicapua Siegel, MD, discusses the current and future role for mezigdomide in the multiple myeloma treatment paradigm.

Jonathan R. Strosberg, MD, discusses the evaluation of cabozantinib vs placebo in patients with advanced gastrointestinal neuroendocrine tumors.

Daniel DeAngelo, MD, PhD, discusses data supporting the FDA approval of obe-cel for patients with relapsed or refractory B-cell precursor ALL.

Andrew Ip, MD, discusses the importance of making informed clinical decisions when selecting CAR T-cell therapy in older vs younger patients with LBCL.

Yousef Zakharia, MD, discusses the long-term benefits of nivolumab plus ipilimumab according to risk status in clear cell renal cell carcinoma.

Aasma Shaukat, MD, MPH, discusses the sensitivity of the PREEMPT CRC blood-based assay in detecting colorectal cancer for patients at average risk.

Mansi R. Shah, MD, highlights the data on the effects of IVIG on infections in patients with relapsed/refractory multiple myeloma treated with teclistamab.

Paul E. Oberstein, MD, discusses the efficacy and safety of pamrevlumab plus chemotherapy in first- and second-line PDAC.

Nazli Dizman, MD, explains the rationale for evaluating the impact of CBM588 on the gut microbiome in patients with metastatic RCC.

Hidehito Horinouchi, MD, PhD, discusses safety data for adjuvant alectinib vs chemotherapy in ALK-positive non–small cell lung cancer.

Alexander C.J. Van Akkooi, MD, PhD, FRACS, discusses how discrepancies in local and central pathologic review can expose patients to potential toxicities associated with overtreatment for metastatic melanoma.

Emily Hinchcliff, MD, MPH, discusses the addition of dostarlimab to standard-of-care chemotherapy in patients with advanced/recurrent endometrial cancer.

Guillermo Garcia-Manero, MD, discusses the rationale for investigating the dual inhibition of IRAK4 and FLT3 with emavusertib in MDS and AML

Scott Kopetz, MD, PhD, FACP, discusses findings from the phase 3 BREAKWATER study of frontline encorafenib plus cetuximab with or without chemotherapy in BRAF V600E–mutated metastatic CRC.

Gao-Jun Teng, MD, discusses findings from the phase 2 CARES-005 trial of TACE plus camrelizumab and rivoceranib vs TACE alone in patients with unresectable HCC.

Emily M. Hinchcliff, MD, MPH, discusses future research directions regarding the role of PARP inhibitors for the treatment of patients with ovarian cancer.

Alvaro Alencar, MD, explains the rationale of a phase 1 trial investigating NX-5948, a BTK degrader, in chronic lymphocytic leukemia.

Marcia Cruz-Correa, MD, PhD, AGAF, FASGE, discusses the FDA approval of tislelizumab plus chemotherapy for metastatic gastric or GEJ adenocarcinoma.

Mohammed Najeeb Al Hallak, MD, MS, discusses treatment considerations for patients with HCC and the associated risks of cirrhosis and portal hypertension.

Alberto Montero, MD, MBA, CPHQ, discusses unmet treatment needs for patients with HER2-positive metastatic breast cancer.

Wojciech Jurczak, MD, discusses the role of nemtabrutinib in the management of relapsed or refractory follicular lymphoma.

Adam E. Singer, MD, PhD, discusses factors that inform the choice between IO/IO and IO/TKI regimens for patients with renal cell carcinoma.

John M. Burke, MD, discusses the barriers to initiating venetoclax-based regimens for chronic lymphocytic leukemia.

Bradley McGregor, MD, discusses next steps for research with ipilimumab plus nivolumab for patients with diverse bladder cancer histologies.

Ira Zackon, MD, discusses the real-world use of bispecific antibodies for patients with R/R multiple myeloma in the community oncology setting.